TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity. Hao JL, He JQ, Hu H, Zhu ZH, et al. Oncogene 2025 Aug 4. doi: 10.1038/s41388-025-03517.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hao JL, He JQ, Hu H, Zhu ZH, et al. TLL1 knockdown attenuates prostate cancer progression by enhancing antitumor immunity. Oncogene 2025 Aug 4. doi: 10.1038/s41388-025-03517.
PMID: 40760092